
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
– $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts – – Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI®, a revenue- …